Kelebihan Makanan Liburan? Stimulator Bioelektronik Mungkin Segera Membantu [translated Title here]

Today, an increasing amount of people are living an increasingly sedentary and gluttonous lifestyle.  Whether this is due to more screen time, work-from-home practices, or something else entirely, the result is the same – Obesity has become an epidemic.  While smoking topped the list of leading causes of preventable deaths for ages, it was in the 1990s that Obesity began to vie for this unwanted moniker.  By the 2000s, it became the number one cause of preventable deaths and has stayed atop the list ever since.  As a result, pharmaceutical companies and biotech researchers have been hard at work ever since, developing solutions for dealing with the situation.  One of the latest approaches involves ‘bioelectronic stimulators’ that look to trick the brain into thinking one is full when ingested.

Memahami Stimulator Bioelektronik

In a recent paper titled “Stimulator Bioelektronik yang Dapat Ditelan Bergetar Memodulasi Reseptor Peregangan Lambung untuk Ilusori kepuasan“, released through science.org, researchers detail a new approach to tackling obesity.  Rather than attempting to manipulate the body’s endocrine system or through “invasive surgical and endoscopic interventions,” this approach makes use of what they call ‘bioelectronic stimulators’ – essentially pills that vibrate while in the stomach that are safe to pass through the gastrointestinal tract.

The purpose of these pills, which the researchers call the “Vibrating Ingestible BioElectronic Stimulator (VIBES)”, is to stimulate nerve endings within the stomach lining that play a role in ‘feeling full’.  While human trials have not yet begun, it is shared that early tests were highly successful in decreasing intake among pigs by as much as 40%.  The study provides the following description of the process involved with these pills.

“VIBES dirancang untuk dikonsumsi secara oral, untuk mempertahankan kontak dengan lapisan lambung, untuk diaktifkan saat terendam dalam cairan lambung, untuk bergetar dengan amplitudo yang cukup untuk merangsang IGLE lambung selama periode waktu tertentu, dan untuk melewati saluran pencernaan dengan aman.”

It should be noted that while VIBES may represent a gentler approach to obesity than existing options at this time, these tests were completed with pigs and not humans.  It should be interesting moving forward to see if such an approach can be brought to fruition, as effective obesity treatments have already proven both life-changing for users and sangat menguntungkan for companies like Novo Nordisk.

Mengapa Obesitas Begitu Buruk?

What makes Obesity so terrible is the strain that it puts on not only the healthcare system but each and every system within the human body.  Increased fat leads to atherosclerosis, which results in strokes, heart attacks, high blood pressure, and more.  It is also typically accompanied by diabetes, which means nerve issues, gait issues, sugar comas, and ketoacidosis.  It results in systemic inflammation, acid reflux, and more.  The list goes on and on and on.

Another reason it has become so dangerous is one that is not as commonly discussed (and often derided when it is) – normalization.  There are always exceptions that may result in obesity being out of a person’s control.  However, the fact that 42% of North Americans live with it, alongside an age that promotes acceptance of all body types, has resulted in obesity being viewed in a normal light.  This means that not only is obesity accompanied by a litany of terrible health ailments, is has become prevalent with a decreased awareness surrounding the need to do something about it.

Solusi Saat Ini?

On paper, the solution to obesity looks simple enough – burn more calories than you take in.  Traditionally, this means eating less, eating healthy, and exercising more.  This isn’t always possible though, which has resulted in various other solutions being developed over the years.  The following are examples of these.

Operasi: In the most extreme cases, some individuals turn to solutions like gastric bypass or gastric banding surgeries.  These typically involve restricting the stomach size and preventing overindulging in food.

Farmasi: Before invasive surgeries are considered, many are now turning to pharmaceutical solutions like semaglutide (i.e., Ozempic and Wegovy).  Medications such as these work by manipulating the endocrine system and its effect on appetite, digestion, and blood sugar.

Naturally, each of these approaches can have major side-effects of their own, making the preferred approach towards obesity lifestyle changes instead.

Perusahaan BioTech Teratas

As it stands, a bioelectronic stimulator used to decrease appetite is nothing more than a potential solution to obesity.  The issue remains, however, and pharmaceutical companies are hard at work developing effective approaches like semaglutide.  The following are a few examples of these.

*Angka-angka di bawah ini akurat pada saat penulisan dan dapat berubah.  Setiap investor potensial harus memverifikasi metrik*

1. Novo Nordisk

NVO Grafik Harga

Novo Nordisk telah membuat kemajuan signifikan di pasar pengobatan obesitas, terutama dengan perawatan injeksi penurunan berat badan yang disetujui FDA, Wegovy. Penjualan perusahaan dari produk perawatan obesitas melonjak 174% selama sembilan bulan pertama tahun 2023, mencerminkan permintaan tinggi untuk pengobatan obesitas.

2. Pfizer, Inc.

PFE Grafik Harga

Pfizer (PFE ), bersama perusahaan farmasi besar lainnya seperti Novartis dan Amgen (AMGN ), secara aktif mengembangkan pengobatan obesitas mereka sendiri. Pertumbuhan potensial pasar obat anti-obesitas, yang diproyeksikan mencapai $100 miliar pada tahun 2030, telah menarik perusahaan-perusahaan ini untuk berinvestasi dalam mengembangkan solusi bagi obesitas.

3. Eli Lilly and Company

LLY Grafik Harga

Eli Lilly and Company (LLY ) telah mengembangkan injeksi Zepbound™ (tirzepatide), yang telah menerima persetujuan FDA. Pengobatan ini menonjol karena menjadi yang pertama dalam jenisnya yang mengaktifkan reseptor hormon GIP (glukosa-dependen insulinotropik polipeptida) dan GLP-1 (glukagon-like peptide-1), menjadikannya tambahan unik dalam rangkaian pengobatan obesitas.
[translated Content here]